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INTRODUCTION: There are various approaches to the treatment of cutaneous tumors; one of them is treatment with imiquimod, 
a synthetic toll-like receptor agonist with a low molecular weight that offers a topical, noninvasive, and non-surgical therapeutic 
option. The main objective of our study was to provide data on 89 patients who used a 5% imiquimod cream for the treatment of 
cutaneous tumors at the Cutaneous Oncology Group of the Dermatology Department of Hospital das Clinicas from 2003 to 2008.
MATERIALS AND METHODS: Here, we present our experience in the treatment of 123 cutaneous tumors of various types, 
including basal cell carcinoma (BCC), squamous cell carcinoma (SCC), Bowen’s disease, erythroplasia of Queyrat, Paget’s disease, 
and trichoepithelioma, with 5% imiquimod cream from 2003 to 2008 in the Cutaneous Oncology Group of the Dermatology De-
partment of Hospital das Clinicas. Patients were divided into two separate groups according to their diagnosis and comorbidities; 
these comorbidities included epidermodysplasia verruciformis, xeroderma pigmentosum, albinism, basal cell nevus syndrome, 
Brooke-Spiegler syndrome, HIV, chronic lymphocytic leukemia, B-cell lymphoma, and kidney transplantation. Treatment duration, 
response to imiquimod, follow-up, recurrence, and local and systemic reactions associated with use of the drug were analyzed. 
Epidemiological data were obtained and cure rates were calculated.
RESULTS: The ratio of women to men was 1.28:1, and the mean age was 63.1 years. Tumors were located mainly on the face, 
back, trunk, and legs. For patients with comorbidities, the overall cure rate was 38%. These specific patients demonstrated cure 
rates of 83.5% for superficial BCC and 50% for Bowen’s disease. Aggressive BCC and superficial and nodular BCC did not pres-
ent a good response to treatment. Trichoepitheliomas and nodular BCC showed a partial response, and erythroplasia of Queyrat 
showed a complete response. For patients without comorbidities, the overall cure rate was 73%. For these patients, the cure rates 
were 85.7% for superficial and nodular BCC, 88% for superficial BCC, 57% for Bowen’s disease, 50% for nodular BCC, and 50% 
for aggressive BCC. One SCC lesion demonstrated a complete response, and tumors caused by Paget’s disease and erythroplasia of 
Queyrat presented a partial response. None of the tumors considered as clinically cured recurred. Thirty-seven lesions demonstrated 
no response to imiquimod. Having a cutaneous comorbidity, high-risk tumors such as mixed aggressive BCC (sclerodermiform or 
micronodular), nodular BCC, or Bowen’s disease, and presenting no local reaction to imiquimod were considered as risk factors for 
a worse prognosis. We demonstrate that patients with no response to imiquimod, even when they demonstrated no local reaction, 
can undergo another cycle of six weeks of imiquimod treatment and show a complete response. The healing pattern led to good 
cosmetic outcomes, and the side effects were tolerable.
CONCLUSIONS: Our experience confirms imiquimod as an effective treatment option for several types of cutaneous tumors, 
especially in patients without the cutaneous comorbidities cited above and with low-risk tumors. Imiquimod has a relatively low 
cost compared to other therapeutic options and can be delivered via ambulatory care to patients with surgery contraindications, 
and its side effects are tolerable.
KEYWORDS: Non-melanoma skin cancer; Imiquimod; Immunomodulator; Basal cell carcinoma; Immunotherapy.
INTRODUCTION
Imiquimod is capable of enhancing both innate and cell-
mediated immune pathways. It stimulates the innate immune 
response through the induction, synthesis, and release of 
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cytokines. Imiquimod activates antigen-presenting cells 
such as monocytes, macrophages, B cells, and dendritic 
cells by activating toll-like receptors (TLRs), which are a 
family of pathogen recognition receptors. The stimulation 
of TLRs results in the activation of a signaling cascade that 
recruits protein kinases and transcription factors, ultimately 
promoting maturation and the secretion of interleukins 
(ILs) 12 and 18 and interferon-alpha (IFN-α) by target cells. 
The secretion of these cytokines induces the secretion of 
interferon-gamma (IFN-α) by naive T cells, resulting in 
the development of a Th1 lymphocyte-mediated immune 
response. Thus, imiquimod’s effect on the cell-mediated 
immune response is mediated by an indirect stimulation of 
the production of the Th1 cytokine IFN-α.1
An additional effect of imiquimod is its activation of 
Langerhans cells: it promotes their migration to the regional 
lymph node, thus potentially enhancing antigen presentation 
to T cells.
Imiquimod 5% cream was initially approved in the US 
in 1997 as a topical treatment for external anogenital warts; 
after further clinical studies, it was approved in 2004 as a 
possible treatment for superficial basal cell carcinoma and 
actinic keratoses.8 Imiquimod’s antitumorigenic effects 
are mediated by the up-regulation of local IFN- α levels, 
suggesting that increased natural killer cell activity may 
be an important factor for both spontaneous and induced 
regression of basal cell carcinomas.2 Many studies have 
tested and discussed the use of imiquimod on several types 
of cutaneous tumors. Based on the results of previous 
studies, we reviewed all patients who had used imiquimod 
in our service. 
MATERIALS AND METHODS
A retrospective study was designed to analyze the use 
of imiquimod on cutaneous tumors at the Dermatology 
Department of Hospital das Clinicas. A total of 574 patients 
were identified by the primary screening criterion: use 
of imiquimod in our hospital between January 2003 and 
October 2008 for HPV, pre-tumor, and tumor treatment. 
After review of the biopsy results for cutaneous tumors, 
138 patients were retained for our analysis. Forty-two 
patients were excluded because of incomplete data, and 
seven were excluded because they were treated for lesions 
that were not tumors, such as actinic or seborrheic keratoses 
and warts. The records of 89 patients, corresponding to 
123 lesions, were analyzed. Records of demographic data, 
biopsy results, treatment regimens, tumor outcomes, and 
adverse events were obtained. The data were entered into a 
spreadsheet (Excel) in order to tabulate descriptive statistics. 
The duration of treatment was calculated from the time a 
patient was initially prescribed topical 5% imiquimod cream 
until the time that the tumor was determined to be clinically 
cured or the treatment was stopped due to failure (minimum 
treatment threshold of six weeks). The administration 
frequency varied from five to seven times per week. The 
follow-up period was calculated from the date that the 
tumor was judged as cured or not (after treatment) to the last 
observation available in the clinical records. Response rates 
were delineated by clinical examination or by histological 
evaluation of punch biopsies obtained from affected tumor 
sites.
RESULTS
Of the 89 patients, 56.2% (n=50) were women, and 
43.8% (n=39) were men. The ratio of women to men was 
1.28:1. The majority of patients were white (n=60). The 
mean age was 63.1 years (11-92 years). The 123 individual 
lesions studied were classified based on the tumor type 
and the associated comorbidity; the treatment duration in 
weeks, response to imiquimod, months of follow-up, and 
recurrence of lesions were analyzed. Patients were divided in 
two groups based on whether or not they had comorbidities.
A total of 54 tumors (44.2%) were located on the face, 
18 (15%) on the back, 18 (15%) on the trunk, 13 (11%) on 
the legs, 10 (8.4%) on the arms, six (5%) on the neck, two 
(1.5%) on the penis, one on the lower lip, and one ion the 
axillae (0.08% each).
There were 29 lesions from 19 patients with comorbi-
dities; these comorbidities included epidermodysplasia 
verruciformis (n=7),  albinism (n=3),  xeroderma 
pigmentosum (n=1), Brooke-Spiegler syndrome (n=2), 
basal cell nevus syndrome (n=10), HIV (n=1), chronic 
lymphocytic leukemia (n=1), B-cell lymphoma (n=2), and 
kidney transplantation (n=2). The lesions found in patients 
with comorbidities included Bowen’s disease (n=6), 
superficial BCC (n=6), superficial and nodular BCC (n=6), 
aggressive (sclerodermiform or micronodular) basal cell 
carcinoma (n=7), nodular BCC (n=1) trichoepithelioma 
(n=2), and erythroplasia of Queyrat (n=1). Forty-five 
percent of these lesions (n=13) showed no response to 
imiquimod, 17.5% (n=5) showed a partial response, and 38% 
(n=11) showed a complete response. In terms of clinical or 
histologic cure, the cure rates were 50% (n=6) for Bowen’s 
disease and 83.5% (n=6) for superficial BCC. Superficial 
and nodular BCC (n=6) demonstrated no response and 
a partial response in 83.5% and 16.5% of patients with 
comorbidities, respectively. Aggressive BCC displayed 
no response to imiquimod in 71.5% of these patients and 
a complete response in 28.5%. Erythroplasia of Queyrat 
presented a complete response to treatment, and nodular 
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BCC and trichoepitheliomas demonstrated a partial response. 
No recurrence was detected, and patients who showed 
no response or only a partial response to treatment were 
treated with another therapeutic method soon after the use 
of imiquimod was terminated (Table 1).
There were 94 lesions from 70 patients without 
comorbidities; these lesions included superficial BCC (n=51), 
superficial and nodular BCC (n=21), nodular BCC (n=6), 
aggressive (sclerodermiform or micronodular) BCC (n=6), 
Bowen’s disease (n=7), SCC (n=1), erythroplasia of Queyrat 
(n=1), and Paget’s disease (n=1). Seventy-three percent of 
the patients without comorbidities demonstrated a complete 
response to treatment, and 27% showed no response. 
The cure rates were 85.7% and 78.4% for nodular/
superficial basal cell carcinoma and superficial BCC, 
respectively. Among the cured patients, inclusion of the five 
patients with superficial BCC who were treated twice with 
imiquimod (12 weeks of use) raised the cure rate to 88%. 
Paget’s disease and erythroplasia of Queyrat presented a 
partial response to treatment. The cure rate was 57% for 
Bowen’s disease and 50% for nodular BCC. Surprisingly, 
mixed BCC with an aggressive sclerodermiform or 
micronodular component displayed a cure rate of 50%, and 
one SCC lesion showed a complete response. One important 
finding was that, of the tumors considered clinically cured, 
none recurred during the extended follow-up period.
Patients who showed no response or only a partial 
response to treatment were treated via another therapeutic 
option. Thirty-seven lesions did not respond to imiquimod; 
they were subsequently treated with surgery (n=15), 
photodynamic therapy (n=10), imiquimod (n=7), and 
cryotherapy (n=1). Of these 37 lesions, 23 were from 
patients without comorbidities, and 14 were from patients 
with comorbidities; this corresponds to nearly half (48.3%) 
of all tumors found on patients with comorbidities. Fourteen 
lesions (37.8%) were located on the face, seven (19%) on the 
back, five (13.5%) on the neck, four (10.8%) on the trunk, 
four (10.8%) on the legs, two (0.05%) on the arms, and one 
(0.025%) on the lower lip. Among all the lesions located 
on the back, 38.8% recurred, compared to recurrence rates 
of 30.8% on the legs, 26% on the face, 22.2% on the trunk, 
and 20% on the arms. Tumors located on the penis and 
in theaxillae presented no recurrence, and the only lesion 
found on the lower lip recurred. Neck lesions exhibited the 
highest levels of recurrence: 83.3% for a total of six lesions. 
Eleven lesions were superficial BCC, nine were superficial 
and nodular BCC, eight were mixed BCC with an aggressive 
component, six were Bowen’s disease, and three were 
nodular BCC. Of all the aggressive BCC lesions, 61.5 % 
recurred, compared to 42.8% of nodular BCC lesions, 41.5% 
Table 1 - Usage of topical 5% imiquimod cream in patients with comorbidities























Albinism (02) Superficial BCC (03) 08 weeks 02 complete; 01 none 24.6 months
Xeroderma Pigmentosum (01) Sclerodermiform
BCC -positive margin (01)
08 weeks Complete 26 months
Brooke-Spiegler syndrome (02) Trichoepithelioma (02) 32 weeks Partial 10 months













HIV (01) Erythroplasia of Queyrat (01) 03 weeks Complete 03 months
Chronic lymphocytic leukemia (01) Superficial/nodular BCC (01) 06 weeks No 10 months









B–cell Lymphoma (01) Superficial BCC (02) 06 weeks 02 complete 12 months
BCC: basal cell carcinoma
964
CLINICS 2009;64(10):961-6Treatment of cutaneous tumors with topical 5% imiquimod cream
Alessi SS et al.
of Bowen’s disease lesions, 33.3% of superficial and nodular 
lesions, and 19.3% of superficial BCC lesions (Table 2).
Of the seven patients who were treated with imiquimod 
twice, five presented a complete response after the second 
cycle of use, which brought the total duration of treatment 
to twelve weeks; the other two patients did not show any 
response. We were unable to determine the method used to 
treat three lesions that showed no response, and one patient 
refused to try another treatment after imiquimod failed. 
Patients with Paget´s disease and erythroplasia of Queyrat 
showed a partial response and demonstrated good results 
after treatment with PDT.
 Eleven patients did not have any local reactions, such as 
erythema, vesiculation, erosions, scaling, crusting, burning, 
and itching. These patients had a total of 15 tumors, eight 
of which (53.3%) presented no response to imiquimod and 
had to be treated via other therapeutic methods. Two of these 
eight tumors were treated with another cycle of imiquimod, 
demonstrating a complete response after the second cycle 
of treatment.
The majority of patients presented mild (itching, 
erythema, and scaling) to moderate (intense erythema, 
crusting, vesicles, erosion) local skin reactions that were 
completely tolerable and healed spontaneously post-
treatment. Only three patients experienced systemic 
reactions, such as nausea, headache, and flu-like symptoms; 
these side effects did not interfere with the treatment. 
Two patients were subjected to curettage: one was 
affected by basal cell nevus syndrome and underwent 
curettage before the application of imiquimod, and the other 
underwent curettage after imiquimod treatment, as the tumor 
was 15 cm2 in size and presented crusting post-treatment. 
The first patient had two tumors (superficial and nodular 
BCC) that demonstrated a partial response to imiquimod, 
and the second had one superficial BCC lesion that showed 
a complete response.
The potential use of imiquimod as an adjuvant treatment 
to surgery may warrant consideration. We described one case 
of sclerodermiform BCC in a patient affected by xeroderma 
pigmentosum with positive histologic lateral margins; the 
lesion demonstrated a complete response to imiquimod 
treatment. 
Another goal of our study was to learn about the healing 
patterns after treatment with 5% imiquimod cream. In almost 
all patients, imiquimod led to good cosmetic outcomes; 
the skin on the cured area usually displayed a normal 
appearance, without scarring or with only mild erythema, 
atrophy, or depigmentation. Some small persistent scars 
were likely due to the initial biopsy; they were almost 
imperceptible.
DISCUSSION
Imiquimod has been recognized as a topical treatment 
for anogenital warts since 1997 and for superficial BCC and 
actinic keratoses since 2004. 
In previous studies of superficial BCC in which the 
tumor site was excised after treatment to confirm tumor 
status, histologic clearance rates ranged from 79% to 82% 
with imiquimod application five or seven times per week for 
six weeks.4 
Another paper reported a cure rate of 90% for superficial 
BCC.12 Our experience revealed initial clinical or histologic 
clearance rates for superficial BCC of 78.4%. Eleven patients 
did not respond to imiquimod, five of whom were treated 
again with another course of six weeks and presented a 
complete response to imiquimod during the second course. 
Classifying these five lesions as cured raised the cure rate of 
superficial BCC to 88%. Three superficial BCC lesions were 
treated for twelve or fourteen weeks; one was treated for six 
weeks, and two were treated irregularly.
A 71% histologic clearance rate was reported in a study 
Table 2 - Usage of topical 5% imiquimod cream in patients without comorbidities








Paget’s disease (01) 01 24 weeks Partial 29 months
Erythroplasia of Queyrat (01) 01 06 weeks Partial 26 months
Level 1 SCC (01) 01 06 weeks Complete 01 month
Bowen’s disease (07) 07 6.1 weeks 04 complete; 03 none 15.4 months
Nodular BCC (05) 06 8.2 weeks 03 complete; 03 none 10.3 months
Mixed BCC with an aggressive component of 
sclerodermiform or micronodular (06)
06 13.5 weeks 03 complete, 03 none 13.6 months
Superf/nodular BCC (18) 21 7.3 weeks 18 complete; 03 none 06.7 months
Superficial BCC (39) 51 6.9 weeks 39 complete; 12 none 15.2 months
BCC: basal cell carcinoma; SCC: squamous cell carcinoma
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of nodular BCC in which imiquimod was applied five times 
per week.5 Our initial clinical tumor cure rates were 85.7% 
for superficial and nodular BCC and 50% for nodular BCC, 
similar to previously reported results; together, these results 
support the use of imiquimod to treat these type of tumors.
The overall initial tumor clinical cure rate reported in 
another paper was 93.4%, in a study including 69 nodular 
BCC, 36 SCC, six basosquamous, and 11 morpheaform 
tumors.8 The overall cure rate for our patients without 
comorbidities was 73%; this included 51 superficial BCC, 
six nodular BCC, 21 superficial and nodular BCC, six 
mixed BCC with an aggressive component, one SCC, and 
seven Bowen’s disease lesions. Somewhat surprisingly, one 
study revealed a 100% clinical tumor cure rate for SCC 
and sclerodermiform BCC.8 The clinical cure rates for our 
patients without comorbidities, even for high-risk tumors 
such as mixed aggressive BCC (cure rate of 50%) and SCC 
(complete response in one tumor), were considerable; these 
results support the usage of topical imiquimod to treat these 
types of lesions in special situations.
Yet, in contrast to the majority of the studies already 
published in the literature, which predominantly limited 
imiquimod treatment to superficial BCC and low-risk 
tumors, we intended to include the whole spectrum of 
cutaneous tumors and comorbidities. By doing so, we 
observed clear differences in response rates and were able 
to describe the use of imiquimod in trichoepitheliomas, 
erythroplasia of Queyrat, and Paget’s disease, all with 
a complete or partial response. There are three cases of 
Paget’s disease treated with imiquimod have been reported 
in the literature (two women and one man), with all patients 
showing complete response. 
One patient whose trichoepitheliomas were treated 
with imiquimod and retinoic acid for three years presented 
80% clearance. There are five papers describing the use 
of imiquimod on erythroplasia of Queyrat. Three patients, 
including one with HIV, showed complete response. These 
data, including the experiences that we describe at our 
dermatology service, support the use of imiquimod in the 
treatment of these lesions.
Patients with epidermodysplasia verruciformis, basal cell 
nevus syndrome, xeroderma pigmentosum, and albinism 
were described in our study. We observed that these 
particular types of patients presented a worse response to 
imiquimod for the treatment of aggressive BCC, nodular 
BCC, and Bowen’s disease. Three studies, comprising 49, 
15, and five patients with Bowen’s disease, reported an 86%, 
73%, and 80% complete response, respectively; these results 
differ from those of our study, in which the cure rate with 
imiquimod was 57%.
Lesions located on the neck, back, or legs and those that 
did not present a local inflammatory reaction also presented 
lower cure rates. Perhaps a deficiency or a decreased 
number of toll-like receptors at these sites explain this lower 
response; this may occur, for example, due to alterations 
in inflammatory cascades. More studies are needed to 
understand the real cause of this difference in response.
The  cure  ra te  for  les ions  on  pa t ien ts  wi th 
comorbidities was 38%, compared to 73% for patients 
without comorbidities. However, even for patients with 
comorbidities, low-risk tumors such as superficial BCC and 
Bowen’s disease presented excellent cure rates of 86.5% and 
50%, respectively; these results seem to favor histology as 
an important prognostic parameter. Superficial and nodular, 
nodular, mixed and sclerodermiform BCC showed low cure 
rates, especially in patients with basal cell nevus syndrome. 
None of these patients demonstrated a complete response 
to imiquimod, in contrast to the data found in the literature 
showing cure with imiquimod in patients with basal cell 
nevus syndrome. However, we demonstrated cure of some 
lesions in patients with epidermodysplasia verruciformis, 
which has not been reported in the previous literature, and in 
patients with xeroderma pigmentosum (already described). 
There are no reports of imiquimod treatment in 
patients with albinism. We also observed that patients 
with cutaneous comorbidities (basal cell nevus syndrome, 
epidermodysplasia verruciformis, albinism, xeroderma 
pigmentosum, and Brooke-Spiegler syndrome) showed a 
diminished response to treatment compared to patients with 
other types of comorbidities, such as hematologic neoplasia, 
immunosuppression for kidney transplantation, and HIV. 
Therefore, the use of imiquimod in patients with cutaneous 
comorbidities needs to be reviewed based on the specific 
circumstances of each patient.
Worse outcomes were also observed for tumors that did 
not show local reactions: more than half of them displayed 
no response to imiquimod. However, even lesions without 
a local reaction can be repeatedly treated with imiquimod 
and show a complete response during the second course 
of treatment. Seven lesions, including two that did not 
present a local reaction, were treated with imiquimod for a 
second cycle of six weeks, and 71.5% presented a complete 
response during this second course. Therefore, imiquimod 
can be used repeatedly if there is no response in the first 
cycle of treatment; this is especially true for low-risk tumors.
The main advantage of topical treatment of cutaneous 
tumors with 5% imiquimod cream is that it provides an 
option for patients with contraindications to surgery or 
patients with multiple lesions. Furthermore, imiquimod is a 
relatively low-cost treatment with tolerable side effects and a 
high cure rate, especially for patients without comorbidities 
and with low-risk tumors; these patients generally have a 
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better prognosis. However, in selected cases of patients with 
cutaneous comorbidities or high-risk tumors, imiquimod is 
also considered as a supportive therapeutic method. 
CONCLUSIONS
With the increasing incidence of cutaneous tumors, 
especially BCC, imiquimod may offer an alternative 
treatment option that avoids surgical or ablative therapy, 
particularly in patients who present a challenge to surgery 
(the elderly, patients on anticoagulation medication, 
multimorbid patients, patients with multiple lesions, and 
patients with recurrent or incompletely excised tumors). 
Imiquimod presents an alternative for diseases 
traditionally treated by surgery, and it may be an 
important option in the management of increasingly 
common cutaneous malignancies. For patients without 
comorbidities, our study revealed good cure rates for 
superficial BCC and superficial/nodular BCC (88% and 
85%, respectively). Nodular and aggressive BCC and 
Bowen’s disease exhibited lower cure rates (50%, 50%, 
and 57%, respectively). Imiquimod is also considered as 
a good alternative for Paget’s disease, erythroplasia of 
Queyrat, and trichoepitheliomas. For patients with cutaneous 
comorbidities, imiquimod is a good option only for low-risk 
tumors. 
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